Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.38 |
| ▸ | AR | P10275 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593302 | 0.81 | PTGDR2 (0.37) | PTGDR2CYP2C19RXRARXRG | |
| SCHEMBL3609673 | 0.80 | PTGDR2 (0.41) | PTGDR2ARF11RXRARXRB | |
| SCHEMBL3604843 | 0.77 | AR (0.44) | ARPGRRXRARXRBRXRG | |
| SCHEMBL3588945 | 0.76 | PSEN1 (0.34) | PTGDR2RXRARXRG | |
| SCHEMBL23877136 | 0.74 | AR (0.51) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL3594636 | 0.73 | PTGDR2 (0.38) | PTGDR2RXRARXRG | |
| SCHEMBL3603210 | 0.72 | GRIN2B (0.40) | ARRXRARXRBRXRG | |
| SCHEMBL3591226 | 0.71 | CTSS (0.39) | ARPGRF11RXRARXRB | |
| SCHEMBL3596237 | 0.70 | PTGDR2 (0.39) | PTGDR2RXRARXRG | |
| SCHEMBL3602959 | 0.70 | IDH2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | PTGDR2 18/4885AR 283/4885CYP2C19 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.